Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Lumera Corporation Forms New Bioscience Subsidiary and Initiates Review of Partnering Opportunities for the Bioscience Business

Abstract:
Names Industry Veteran, Joseph Vallner, Chairman/CEO

Lumera Corporation Forms New Bioscience Subsidiary and Initiates Review of Partnering Opportunities for the Bioscience Business

BOTHELL, WA | Posted on July 17th, 2007

Lumera Corporation (NASDAQ:LMRA), a leader in the emerging field of nanotechnology, today announced that it has formed a wholly owned subsidiary known as Plexera Bioscience LLC. The new subsidiary will serve as the operations unit of Lumera's bioscience business and will be led by Joseph Vallner, Ph.D., as Chairman and Chief Executive Officer and Tim Londergan, Ph.D., who is the division's current manager, as President and Chief Operating Officer. Lumera has engaged Robert W. Baird & Co., Inc. to assist the company in evaluating partnering and financing alternatives over the coming months.

In early 2006, Lumera created a separate bioscience operating unit within the company to facilitate its drive toward successful market commercialization and the transition from a research and development company. Plexera will remain focused on providing the life sciences market with tools, content, and methods to simplify and accelerate proteomic discovery for therapeutic antibodies as well as predictive biomarkers.

"The formation of Plexera clarifies the purpose, business requirements and market opportunities of both Plexera and Lumera to our investors, customers, and prospective partners," said Tom Mino, President and Chief Executive Officer of Lumera.

Joseph Vallner, a current Lumera board member, will head the subsidiary as Chairman and Chief Executive Officer. Dr. Vallner brings extensive bioscience experience to the job, having worked for 32 years in the pharmaceutical industry as both an academician and as a business leader.

"As a Lumera board member, I've had the opportunity to witness first hand the talent and commitment to succeed on the part of Tim's team. Now, as Chairman and CEO, I look forward to helping Plexera reach its full potential," said Vallner.

Most recently, Vallner served as Chief Executive Officer of Capnia, a private pharmaceutical development company. From 1999 until 2006, he was President and Chief Operating Officer of Cell Genesys, where his responsibilities included research and development as well as clinical, regulatory, manufacturing, and operations. While at Cell Genesys, he also served on the California Healthcare Institute Board of Directors. Dr. Vallner also held various positions including Executive Vice-President and Chief Operating Officer at Sequus Pharmaceuticals, where he was instrumental in leading the company to the launch of two products including Amphotec® and Doxil®, a cancer therapeutic, which is now a $400+ million product. Sequus was subsequently acquired and merged into Alza Corporation. He obtained a Ph.D. in pharmaceutics, an M.S. in physical chemistry, and B.S. in pharmacy from the University of Wisconsin, Madison. His academic career included a post as Assistant Professor then Associate Professor of Pharmaceutics at the University of Georgia.

As Plexera's President and Chief Operating Officer, Dr. Tim Londergan will lead the subsidiary's day-to-day operations. In 2000, Dr. Londergan became Lumera's first employee as a senior chemist. Over the past six years he has been a key driver in the development and marketing of Lumera technology and bio-related products to both research and commercial institutions. As Director of the Bioscience Business Unit, he has also played an important role in establishing Lumera partnerships with the key institutions such as Harvard Medical School, the Medical University of South Carolina, and the Institute of Systems Biology. Londergan earned his Ph.D. in Organic Chemistry from the University of Southern California.

"We are extremely pleased to have Dr. Vallner agree to join the company as Chairman and CEO bringing his breadth of experience as a business leader in the sector and expect that his understanding of running bioscience centered businesses will have an immediate impact," continued Mino. "We are also grateful to have the continued leadership of Tim Londergan. In his new, expanded role, we expect Tim to be at the forefront of the continued progress of the company."

Rounding out the management team is a group of seasoned professionals bringing experience from successful companies such GE Healthcare, Bio-Rad, Thermo-Nicolet Instrument Corporation, ICOS, Life Technologies, and Spacelabs. The team includes Dr. Michael Cicirelli, Director of Application Development; Ronald Dudek, Director of Business Development; and Todd Schwoerer, Director of Operations.

####

About Lumera Corporation
Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices.

Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company’s forward-looking statements include the following: market acceptance of our technologies and products; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company’s SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.

For more information, please click here

Contacts:
(Investor Relations)
Lumera Corporation
Hélène F. Jaillet, Ph.D.
425-398-6546
or
(Media)
The Summit Group Communications
Todd Wolfenbarger
801-595-1155
Cell: 801-244-9600

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Announcements

New quantum phenomena in graphene superlattices September 18th, 2017

Do titanium dioxide particles from orthopedic implants disrupt bone repair? September 16th, 2017

Hydrogen power moves a step closer: Physicists are developing methods of creating renewable fuel from water using quantum technology September 15th, 2017

Corrosion in real time: UCSB researchers get a nanoscale glimpse of crevice and pitting corrosion as it happens September 14th, 2017

Appointments/Promotions/New hires/Resignations/Deaths

180 Degree Capital Corp. Appoints Investment Banking Veteran Parker Weil to Its Board of Directors August 2nd, 2017

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Alliances/Trade associations/Partnerships/Distributorships

Leti and Partners in PiezoMAT Project Develop New Fingerprint Technology for Highly Reliable Security and ID Applications: Ultra-high Resolution Pressure Sensing Uses Matrices of Vertical Piezoelectric Nanowire To Reconstruct the Smallest Features of Human Fingerprints September 5th, 2017

Phenom-World selects Deben to supply a tensile stage as an accessory to their range of desktop SEMs August 29th, 2017

Oxford Instruments Plasma Technology announces a new partner in Korea August 15th, 2017

Moving at the Speed of Light: University of Arizona selected for high-impact, industrial demonstration of new integrated photonic cryogenic datalink for focal plane arrays: Program is major milestone for AIM Photonics August 10th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project